CRTAC1

Across TCGA pan-cancer cohorts, CRTAC1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of CRTAC1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CRTAC1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CRTAC1 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, LSCC, and LUAD are the cancer types where CRTAC1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CRTAC1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	−1.014	<.001	11	view →
LSCC	Male	II,III,IV	−1.375	<.001	9	view →
LUAD	Female	II,III,IV	−1.212	<.001	9	view →
COAD	All	All	−0.350	<.001	9	view →
PDAC	All	All	+0.461	<.001	5	view →
OV	All	All	−0.878	<.001	2	view →
CCRCC	Male	III,IV	−0.206	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

CRTAC1–HNSC

Open the HNSC breakdown →